{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:34:03Z","timestamp":1794090843478,"version":"4.8.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.11.041","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T09:22:53Z","timestamp":1606209773000},"page":"402-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-lasting heterologous antibody responses after sequential vaccination with A\/Indonesia\/5\/2005 and A\/Vietnam\/1203\/2004 pre-pandemic influenza A(H5N1) virus vaccines"],"prefix":"10.1016","volume":"39","author":[{"given":"Anu","family":"Haveri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Ikonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carita","family":"Savolainen-Kopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Julkunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2020.11.041_b0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/viro.1999.9820","article-title":"Genetic characterization of the pathogenic influenza A\/Goose\/Guangdong\/1\/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong","volume":"261","author":"Xu","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.11.041_b0010","unstructured":"World Health Organization. Monthly Risk Assessment Summary,Influenza at the human-animal interface. 2019 May 10. https:\/\/www.who.int\/influenza\/human_animal_interface\/HAI_Risk_Assessment\/en\/."},{"key":"10.1016\/j.vaccine.2020.11.041_b0015","doi-asserted-by":"crossref","unstructured":"Smith GJ, Donis RO, World Health Organization\/World Organisation for Animal Health\/Food and Agriculture Organization (WHO\/OIE\/FAO) H5 Evolution Working Group. Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013-2014. Influenza Other Respir Viruses. 2015 Sep;9(5):271-6. https:\/\/dx.doi.org\/10.1111%2Firv.12324.","DOI":"10.1111\/irv.12324"},{"issue":"7","key":"10.1016\/j.vaccine.2020.11.041_b0020","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1473-3099(16)00153-5","article-title":"Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997\u20132015: a systematic review of individual case data","volume":"16","author":"Lai","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.041_b0025","unstructured":"World Health Organization. Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness. 2019 Sep 30. https:\/\/www.who.int\/influenza\/vaccines\/virus\/characteristics_virus_vaccines\/en\/."},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2020.11.041_b0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.vetmic.2012.12.025","article-title":"Characterization of three H5N5 and one H5N8 highly pathogenic avian influenza viruses in China","volume":"163","author":"Zhao","year":"2013","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2020.11.041_b0035","doi-asserted-by":"crossref","unstructured":"Qi X, Cui L, Yu H, Ge Y, Tang F. Whole-Genome Sequence of a Reassortant H5N6 Avian Influenza Virus Isolated from a Live Poultry Market in China, 2013. Genome Announc. 2014 Sep 11;2(5). https:\/\/doi.org\/10.1128\/genomeA.00706-14.","DOI":"10.1128\/genomeA.00706-14"},{"issue":"17","key":"10.1016\/j.vaccine.2020.11.041_b0040","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1128\/JVI.00653-15","article-title":"Newly Emergent highly pathogenic H5N9 subtype avian influenza A virus","volume":"89","author":"Yu","year":"2015","journal-title":"J Virol."},{"issue":"187","key":"10.1016\/j.vaccine.2020.11.041_b0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.vetmic.2016.03.012","article-title":"Highly pathogenic avian influenza viruses H5N2, H5N3, and H5N8 in Taiwan in 2015","volume":"1","author":"Lee","year":"2016","journal-title":"Vet. Microbiol."},{"issue":"6","key":"10.1016\/j.vaccine.2020.11.041_b0050","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jinf.2015.09.004","article-title":"Symptoms seem to be mild in children infected with avian influenza A (H5N6) and other subtypes","volume":"71","author":"Chen","year":"2015","journal-title":"J. Infect."},{"issue":"5","key":"10.1016\/j.vaccine.2020.11.041_b0055","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMc1502983","article-title":"Human Infection with a Novel Avian Influenza A(H5N6) Virus","volume":"373","author":"Yang","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2020.11.041_b0060","unstructured":"World Health Organization. Monthly Risk Assessment Summary,Influenza at the human-animal interface. 2019 Sep 27. https:\/\/www.who.int\/influenza\/human_animal_interface\/HAI_Risk_Assessment\/en\/."},{"issue":"3","key":"10.1016\/j.vaccine.2020.11.041_b0065","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2009.10.019","article-title":"Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1\/2 clinical trial","volume":"28","author":"Keitel","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2020.11.041_b0070","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/infdis\/jiq174","article-title":"Immunogenicity profile of a 3.75-\u03bcg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial","volume":"203","author":"Heijmans","year":"2011","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2020.11.041_b0075","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jfma.2011.11.009","article-title":"Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population","volume":"110","author":"Hwang","year":"2011","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.vaccine.2020.11.041_b0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-2659.2012.00349.x","article-title":"An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults","volume":"7","author":"Gillard","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"10.1016\/j.vaccine.2020.11.041_b0085","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.3390\/v4113227","volume":"4","author":"Chichester","year":"2012","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.vaccine.2020.11.041_b0090","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/CVI.00373-12","article-title":"Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A\/H5N1 prepandemic influenza vaccine in adult and elderly subjects","volume":"19","author":"Bihari","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2020.11.041_b0095","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.vaccine.2011.12.009","article-title":"Safety and immunogenicity of an MF59\u00ae -adjuvanted A\/H5N1 pre-pandemic influenza vaccine in adults and the elderly","volume":"30","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.vaccine.2020.11.041_b0100","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1016\/j.vaccine.2012.07.077","article-title":"Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming","volume":"30","author":"van der Velden","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2020.11.041_b0105","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/CVI.00096-13","article-title":"An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A\/Chicken\/Astana\/6\/05) influenza vaccine is safe and immunogenic in a single dose in humans","volume":"20","author":"Sansyzbay","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"14","key":"10.1016\/j.vaccine.2020.11.041_b0110","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2020.11.041_b0115","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2014.11.018","article-title":"Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial","volume":"33","author":"Langley","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.11.041_b0120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/infdis\/jit498","article-title":"Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population","volume":"209","author":"van der Velden","year":"2014","journal-title":"J Infect Dis"},{"issue":"50","key":"10.1016\/j.vaccine.2020.11.041_b0125","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.vaccine.2008.08.046","article-title":"Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.11.041_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131652","article-title":"Matrix M H5N1 vaccine induces cross-H5 clade humoral immune responses in a randomized clinical trial and provides protection from highly pathogenic influenza challenge in ferrets","volume":"10","author":"Cox","year":"2015","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2020.11.041_b0135","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.vaccine.2015.11.055","article-title":"Cell mediated immune responses following revaccination with an influenza A\/H5N1 vaccine","volume":"34","author":"Mbawuike","year":"2016","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2020.11.041_b0140","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1016\/j.vaccine.2016.08.055","article-title":"Clinical testing of an inactivated influenza A\/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam","volume":"34","author":"Phan","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.11.041_b0145","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/infdis\/jiw310","article-title":"Priming vaccination with influenza virus H5 hemagglutinin antigen significantly increases the duration of T cell responses induced by a heterologous H5 booster vaccination","volume":"214","author":"Hoft","year":"2016","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2020.11.041_b0150","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/21645515.2016.1263410","article-title":"Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A\/H5N1 vaccine) in healthy adults","volume":"13","author":"Song","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2020.11.041_b0155","first-page":"ofz107","article-title":"Safety and immunogenicity of MF59-adjuvanted cell culture-derived A\/H5N1 subunit influenza virus vaccine: dose-finding clinical trials in adults and the elderly. Open Forum","volume":"6","author":"Frey","year":"2019","journal-title":"Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2020.11.041_b0160","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.041_b0165","doi-asserted-by":"crossref","unstructured":"Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, et al. Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant. Open Forum Infect Dis. 2014 Oct 8;1(3):ofu091. https:\/\/doi.org\/10.1093\/ofid\/ofz107.","DOI":"10.1093\/ofid\/ofu091"},{"issue":"3","key":"10.1016\/j.vaccine.2020.11.041_b0170","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41541-018-0076-2","article-title":"AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization","volume":"1","author":"Khurana","year":"2018","journal-title":"NPJ Vac"},{"issue":"1","key":"10.1016\/j.vaccine.2020.11.041_b0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-019-0114-8","article-title":"Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost","volume":"4","author":"Levine","year":"2019","journal-title":"NPJ Vac"},{"issue":"10","key":"10.1016\/j.vaccine.2020.11.041_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013329","article-title":"Genetic diversity of the 2009 pandemic influenza A(H1N1) viruses in Finland","volume":"5","author":"Ikonen","year":"2010","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.vaccine.2020.11.041_b0185","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/molbev\/msw054","article-title":"MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger datasets","volume":"33","author":"Kumar","year":"2016","journal-title":"Mol Biol Evol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.11.041_b0190","first-page":"406","article-title":"The neighbor-joining method: a new method for reconstructing phylogenetic trees","volume":"4","author":"Saitou","year":"1987","journal-title":"Mol Biol Evol"},{"issue":"30","key":"10.1016\/j.vaccine.2020.11.041_b0195","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1073\/pnas.0404206101","article-title":"Prospects for inferring very large phylogenies by using the neighbor-joining method","volume":"101","author":"Tamura","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.11.041_b0200","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0076-6879(93)24035-S","article-title":"Analysis of DNA sequence data: phylogenetic inference","volume":"224","author":"Hillis","year":"1993","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2020.11.041_b0205","unstructured":"World Health Organization, Global influenza surveillance network. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva, Switzerland: World Health Organization; 2011. https:\/\/www.who.int\/influenza\/gisrs_laboratory\/manual_diagnosis_surveillance_influenza\/en\/."},{"issue":"20","key":"10.1016\/j.vaccine.2020.11.041_b0210","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1016\/j.vaccine.2019.03.078","article-title":"Seasonal influenza vaccines induced high levels of neutralizing cross-reactive antibody responses against different genetic group influenza A(H1N1)pdm09 viruses","volume":"37","author":"Haveri","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.041_b0215","unstructured":"World Health Organization. WHO activities in avian influenza and pandemic influenza preparedness January - December 2006. WHO 2007. https:\/\/www.who.int\/influenza\/resources\/documents\/pip_activities\/en\/."},{"issue":"8","key":"10.1016\/j.vaccine.2020.11.041_b0220","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2217\/fvl.15.62","article-title":"H5N1 influenza virulence, pathogenicity and transmissibility: what do we know?","volume":"10","author":"Neumann","year":"2015","journal-title":"Future Virol"},{"issue":"7250","key":"10.1016\/j.vaccine.2020.11.041_b0225","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature08182","article-title":"Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic","volume":"459","author":"Smith","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.11.041_b0230","unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19) Weekly Epidemiological Update. 2020 Oct 5. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"issue":"13","key":"10.1016\/j.vaccine.2020.11.041_b0235","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"issue":"9587","key":"10.1016\/j.vaccine.2020.11.041_b0240","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"issue":"45","key":"10.1016\/j.vaccine.2020.11.041_b0245","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1016\/j.vaccine.2009.01.040","article-title":"Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.041_b0250","doi-asserted-by":"crossref","unstructured":"Levine MZ, Holiday C, Liu F, Jefferson S, Gillis E, Bellamy AR, et al. Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans. J Infect Dis. 2017 Sep 15;216(suppl_4):S555-9. https:\/\/doi.org\/10.1093\/infdis\/jix001.","DOI":"10.1093\/infdis\/jix001"},{"issue":"5","key":"10.1016\/j.vaccine.2020.11.041_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010864","article-title":"Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus","volume":"5","author":"Buchy","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.11.041_b0260","unstructured":"World Health Organization. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases. 2007 Aug. https:\/\/www.who.int\/influenza\/resources\/documents\/h5n1_laboratory_procedures\/en\/."},{"issue":"2","key":"10.1016\/j.vaccine.2020.11.041_b0265","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jviromet.2010.11.024","article-title":"Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus","volume":"171","author":"Grund","year":"2011","journal-title":"J Virol Methods"},{"issue":"14","key":"10.1016\/j.vaccine.2020.11.041_b0270","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/1471-2334-14-414","article-title":"Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore","volume":"28","author":"Hsu","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2020.11.041_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131531","article-title":"Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children","volume":"10","author":"Verschoor","year":"2015","journal-title":"PLoS ONE"},{"issue":"20","key":"10.1016\/j.vaccine.2020.11.041_b0280","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa0906453","article-title":"Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus","volume":"361","author":"Hancock","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.11.041_b0285","doi-asserted-by":"crossref","unstructured":"Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, et al. Reproducibility of Serologic Assays for Influenza Virus A (H5N1). Emerging Infectious Diseases. 2009 Aug 1,;15(8):1250-9. https:\/\/doi.org\/10.3201\/eid1508.081754.","DOI":"10.3201\/eid1508.081754"},{"issue":"8","key":"10.1016\/j.vaccine.2020.11.041_b0290","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1128\/CVI.00278-15","article-title":"International laboratory comparison of influenza microneutralization assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) influenza viruses by CONSISE","volume":"22","author":"Laurie","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2020.11.041_b0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jviromet.2012.03.004","article-title":"Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine","volume":"182","author":"Cheng","year":"2012","journal-title":"J Virol Methods"},{"issue":"11","key":"10.1016\/j.vaccine.2020.11.041_b0300","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/infdis\/jiu359","article-title":"Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children <3 years of age","volume":"210","author":"Nolan","year":"2014","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20314948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20314948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:54:32Z","timestamp":1759402472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20314948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X20314948"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-lasting heterologous antibody responses after sequential vaccination with A\/Indonesia\/5\/2005 and A\/Vietnam\/1203\/2004 pre-pandemic influenza A(H5N1) virus vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}